(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -4.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.49%.
Novavax's revenue in 2026 is $413,796,000.On average, 11 Wall Street analysts forecast NVAX's revenue for 2026 to be $65,155,211,227, with the lowest NVAX revenue forecast at $42,480,122,274, and the highest NVAX revenue forecast at $89,199,349,706. On average, 11 Wall Street analysts forecast NVAX's revenue for 2027 to be $43,596,804,839, with the lowest NVAX revenue forecast at $29,904,660,124, and the highest NVAX revenue forecast at $74,985,976,497.
In 2028, NVAX is forecast to generate $58,656,349,623 in revenue, with the lowest revenue forecast at $41,464,056,602 and the highest revenue forecast at $75,510,503,906.